clinical trial · NCT05761444
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
Organon and Co·phase4·completed·n = 137
Atherosclerotic Cardiovascular DiseaseAtozet 10/40 mg or 10/80 mgLipitor 40 mg or 80 mg
brief summary
This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients. We intend to lay the foundation for a standard treatment for these patients through ezetimibe add on lipid-lowering therapy.
started
Jul 26, 2023
primary completion
Sep 4, 2024
completion
Oct 15, 2024
last updated
Sep 9, 2025
official title
A Phase 4, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Effectiveness and Safety of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol